Citi Initiates Coverage on Wyeth (WYE) with a Hold
More News related to WYE
- ARGUS Maintains Hold Rating on Wyeth (WYE)
- Brodsky & Smith, LLC Announces Investigation of Wyeth Corp. for Violation of Federal Securities Laws
- Cohen's SAC Capital Accumulates Stakes in Target (TGT), Pilgrim's Pride (PPC) and Some Financials (STI, FITB, STT)
- JANA Partners 13F Shows New Stakes in Genentech (DNA), Sears (SHLD), Washington Mutual (WM); Adds to Positions in AK Steel (AKS), Focus Media (FMCN), Transocean (RIG); Sells Out of Apple (AAPL), Lehma
- Gates' The Bill and Melinda Gates Foundation Shows New Positions in Crocs (CROX), Dick's (DKS) and Raised Stakes in McDonald's (MCD), FedEx (FDX) and AIG (AIG)
More News related to New Coverage
- ThinkPanmure Starts ON Semiconductor (ONNN) at Buy
- Merrill Lynch Initiates Coverage on Regency Energy Partners (RGNC) with a Neutral
- Morgan Stanley Starts Elan (ELN) at Overweight
- Morgan Keegan Resumes Petrohawk Energy (HK) at Outperform
- Raymond James Starts CA Inc. (CA) at Outperform
Citi initiates coverage on Wyeth (NYSE: WYE) with a Hold. Price target $49.
Citi analyst says, "We expect WYE to shift its business model to specialty markets. We see upside to our estimates from limited US generic competition to Zosyn/EffexorXR. The uptake of Pristiq/Restilor & material pipeline setbacks Pristiq-VMS/Viviant/Aprela/bifeprunox will result in deeper Project Impact cost saving initiatives to facilitate its transformation."
Wyeth is engaged in the discovery, development, manufacture, distribution and sale of a line of products in three primary businesses: Wyeth Pharmaceuticals (Pharmaceuticals), Wyeth Consumer Healthcare (Consumer Healthcare), and Fort Dodge Animal Health (Animal Health).
Related Categories
New CoverageStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
